Circle Pharma has raised $92.5 million in a Series E financing round led by The Column Group, with participation from Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly and Company. The South San Francisco-based clinical-stage biopharmaceutical company will use the funds to advance CID-165, a first-in-class oral macrocyclic cyclin D1 RxL inhibitor, into clinical development. CID-165 is expected to enter clinical trials in Q1 2027 for patients with ER-positive breast cancer. The drug has shown strong anti-tumour activity in preclinical cancer models, both as a monotherapy and in combination with existing treatments. The financing will also support development of Circle Pharma's broader pipeline of cyclin-targeted macrocycles.

OAKLAND, Calif., September 15, 2026--Planted has raised $31.8 million to scale autonomous power deployment, with Piva Capital and RA Capital Management Planetary Health co-leading the round and participation from Breakthrough Energy Ventures, Gigascale Capital, Google, and Khosla Ventures.

Tyra Biosciences has priced a $400 million underwritten offering of common stock and pre-funded warrants. The clinical-stage biotechnology company will sell 9,079,000 shares at $22.03 per share and pre-funded warrants to purchase 9,078,529 shares at $22.029 per share. The offering is expected to close on 15 September 2026. Tyra plans to use the net proceeds to advance its "dabogratinib 3x3" development strategy in low-grade upper tract urothelial carcinoma, intermediate-risk non-muscle invasive bladder cancer, and achondroplasia, alongside supporting preclinical programmes. RA Capital Management led the offering, with participation from new and existing institutional investors including Invus, Commodore Capital, and Janus Henderson Investors. Jefferies, Guggenheim Securities, Cantor, Barclays, and William Blair are acting as joint book-running managers.